Search Results

FAME II Data Show Cost Effectiveness and Improved Outcomes With FFR-Guided PCI

October 24, 2012—St.

St. Jude Medical Begins FAME II Enrollment

May 25, 2010—St.

Two-Year FAME Results Show Benefit of FFR Guidance

September 24, 2009—TCT Daily, the conference newspaper for the Transcatheter Cardiovascular Therapeutics (TCT) 2009 scientific symposium in San Francisco, reported that 2-year results from the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) trial presented at this year's meeting confirm and extend the 1-year results reported at TCT 2008.

St. Jude Medical Commences Enrollment in FAME II Trial

May 25, 2010—At the EuroPCR 2010 conference in Paris, St.

Medtronic Completes Acquisition of CathWorks

April 20, 2026—Medtronic announced it has completed its acquisition of CathWorks, a privately held medical device company focused on the diagnosis and treatment of coronary artery disease with its fractional flow reserve (FFR) diagnostic technology.

ALL-RISE Compares CathWorks’ FFRangio to Invasive Pressure Wire Guidance

April 3, 2026—CathWorks announced 1-year clinical outcomes of the ALL-RISE trial.

FAME 3 Trial Compares FFR-Guided PCI Versus CABG in Three-Vessel CAD

November 4, 2021—The primary results of FAME 3, the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation 3 trial, found that percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) did not meet noninferiority for 1-year adverse events compared to coronary artery bypass grafting (CABG) in patients with three-vessel coronary artery disease (3V-CAD).

CathWorks Announces Completion of Enrollment in FAST-FFR Trial

August 16, 2018—CathWorks Limited announced that its FAST-FFR trial is fully enrolled ahead of schedule.

Economic Evaluation of FAME Confirms Cost Benefit of FFR-Guided PCI

December 16, 2010—St.

SCAI Expert Opinion Explores Angiography-Derived Physiology for Coronary Assessment

February 5, 2026—The Society for Cardiovascular Angiography & Interventions (SCAI) announced the publication of an expert opinion document that examines the evolving role of angiography-derived physiology (ADP) for the assessment and management of coronary artery disease.

FFR Supported by New PCI Guidelines to Treat CAD

January 15, 2010—Pim A.L.

Study Evaluates Performance of Acist's Navvus Microcatheter for FFR

May 17, 2017—Acist Medical Systems Inc., a Bracco Group Company, announced results from the ACIST-FFR study demonstrating the consistent and correlative performance of the company's Navvus microcatheter compared with standard pressure wire fractional flow reserve (FFR) systems.

FFR in Treatment of CAD Supported by New PCI Guidelines

December 16, 2009—In the updated guidelines from the American Heart Association (AHA), the American College of Cardiology (ACC), and the Society for Cardiovascular Angiography and Interventions (SCAI), the level of evidence for fractional flow reserve (FFR)-guided treatment, a physiological measure of coronary stenosis, has been upgraded from a grade "B" to an "A" because of new research that was conducted to determine its efficacy.

FAME 2 Compares FFR-Guided PCI to Medical Therapy in Patients With Stable CAD

November 2, 2017—New results from the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 2 trial found that when compared with medical therapy (MT) alone, percutaneous coronary intervention (PCI) in patients with stable coronary artery disease (CAD) and abnormal fractional flow reserve (FFR) results in better clinical outcomes at similar cost over 3 years of follow-up.